ArticleLeukemia2025

Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis.

Hira Mian et al.PubMed ↗Publisher ↗

No numbers read from the abstract.